Cargando…

Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective

Prostate cancer is a major health issue in western countries and is the second leading cause of cancer death in American men. Prostate cancer depends on the androgen receptor (AR), a transcriptional factor critical for prostate cancer growth and progression. Castration by surgery or medical treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jian, Lin, Biyun, Li, Benyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965587/ https://www.ncbi.nlm.nih.gov/pubmed/35372068 http://dx.doi.org/10.3389/fonc.2022.865350

Ejemplares similares

TMEM158 expression is negatively regulated by AR signaling and associated with favorite survival outcomes in prostate cancers
por: Huang, Jian, et al.
Publicado: (2022)

The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
por: Aragon-Ching, Jeanny B.
Publicado: (2014)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation
por: Su, Ruopeng, et al.
Publicado: (2022)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

Alternol/Alteronol: Potent Anti-cancer Compounds With Multiple Mechanistic Actions
por: Liu, Wang, et al.
Publicado: (2020)

Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy
por: Zhang, Keke, et al.
Publicado: (2018)

The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression
por: Gao, Lin, et al.
Publicado: (2022)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review
por: Petersen, Stine Elleberg, et al.
Publicado: (2021)

Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer
por: Lu, Zongliang, et al.
Publicado: (2021)

Ceramide Regulates Anti-Tumor Mechanisms of Erianin in Androgen-Sensitive and Castration-Resistant Prostate Cancers
por: Trapika, I Gusti Md Gde Surya C., et al.
Publicado: (2021)

Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms
por: Ribelli, Giulia, et al.
Publicado: (2021)

Androgen-Deprivation Therapy and Cardiovascular Disease Risk – The Role of Exercise in Prostate Cancer Treatment
por: Wall, Bradley
Publicado: (2016)

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Jumonji domain-containing protein RIOX2 is overexpressed and associated with worse survival outcomes in prostate cancers
por: He, Chenchen, et al.
Publicado: (2023)

The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis
por: Zhao, Shankun, et al.
Publicado: (2023)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
por: Zhang, Haozhe, et al.
Publicado: (2022)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer
por: Chiang, Pai-Kai, et al.
Publicado: (2021)

Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention
por: Nouri, Mannan, et al.
Publicado: (2014)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
por: Graff, Julie N., et al.
Publicado: (2020)

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
por: He, Yundong, et al.
Publicado: (2018)

The Role of Epstein–Barr Virus in Cervical Cancer: A Brief Update
por: Vranic, Semir, et al.
Publicado: (2018)

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
por: Wang, Zhize, et al.
Publicado: (2020)

Testicular recurrence of oligometastatic prostatic adenocarcinoma after 22 years of androgen deprivation therapy
por: Fortier, Alexa, et al.
Publicado: (2022)

AB010. Metabolic disturbance for prostate cancer therapy
por: Li, Benyi
Publicado: (2018)

Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy
por: Sarkar, Arjun, et al.
Publicado: (2021)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
por: Kattan, Michael W., et al.
Publicado: (2020)

Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer
por: Moll, Jan Matthijs, et al.
Publicado: (2022)

Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer?
por: Atta, Mohamed Adel, et al.
Publicado: (2019)

Human SP-D Acts as an Innate Immune Surveillance Molecule Against Androgen-Responsive and Androgen-Resistant Prostate Cancer Cells
por: Thakur, Gargi, et al.
Publicado: (2019)

Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
por: Denmeade, Samuel R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e7aq4msulaq2018fa2uom42alg